174 related articles for article (PubMed ID: 37878072)
1. Drug levels of VEDOLIZUMAB in patients with pediatric-onset inflammatory bowel disease in a real-life setting.
Hemming-Harlo M; Merras-Salmio L; Nikkonen A; Kolho KL
Eur J Pediatr; 2024 Jan; 183(1):313-322. PubMed ID: 37878072
[TBL] [Abstract][Full Text] [Related]
2. Proactive infliximab is more effective than vedolizumab in inducing fecal calprotectin remission in inflammatory bowel disease.
Fernandes SR; Rodrigues IC; Serrazina J; Botto IA; Bernardo S; Gonçalves AR; Valente A; Moura Santos P; Correia LA; Marinho RT
Scand J Gastroenterol; 2022 Oct; 57(10):1202-1208. PubMed ID: 35599574
[TBL] [Abstract][Full Text] [Related]
3. Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission.
Wang Y; Wang J; Pekow J; Dalal S; Cohen RD; Ollech J; Israel A; Shogan BD; Micic D; Cannon L; Umanskiy K; Hurst R; Hyman N; Rubin DT; Sakuraba A
J Gastroenterol Hepatol; 2019 Dec; 34(12):2090-2095. PubMed ID: 31169926
[TBL] [Abstract][Full Text] [Related]
4. Factors influencing the outcome of vedolizumab treatment: Real-life data with objective outcome measurements.
Mader O; Juillerat P; Biedermann L; Michetti P; Hruz P; Pittet V; Rogler G; Zahnd-Straumann N; Seibold F
United European Gastroenterol J; 2021 Apr; 9(3):398-406. PubMed ID: 33203339
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic drug monitoring in inflammatory bowel disease patients on vedolizumab.
Ansari M; Glassner K; Irani M; Saleh A; Wang L; Ezeana C; Wong S; Perry C; Abraham B
J Dig Dis; 2024 Feb; 25(2):91-99. PubMed ID: 38599667
[TBL] [Abstract][Full Text] [Related]
6. Real-World Outcomes of Patients Starting Intravenous and Transitioning to Subcutaneous Vedolizumab in Inflammatory Bowel Disease.
Lamichhane N; Melas N; Bergqvist V; ; Ekholm NP; Olén O; Ludvigsson JF; Hjortswang H; Marsal J; Eriksson C; Halfvarson J
Dig Dis Sci; 2024 Jun; 69(6):2175-2183. PubMed ID: 38637457
[TBL] [Abstract][Full Text] [Related]
7. Early vedolizumab trough levels at induction in inflammatory bowel disease patients with treatment failure during maintenance.
Liefferinckx C; Minsart C; Cremer A; Amininejad L; Tafciu V; Quertinmont E; Tops S; Devière J; Gils A; van Gossum A; Franchimont D
Eur J Gastroenterol Hepatol; 2019 Apr; 31(4):478-485. PubMed ID: 30672828
[TBL] [Abstract][Full Text] [Related]
8. Vedolizumab Is Safe and Efficacious for the Treatment of Pediatric-Onset Inflammatory Bowel Disease Patients Who Fail a Primary Biologic Agent.
Choi S; Kim ES; Kwon Y; Kim MJ; Choe YH; Choe BH; Kang B
J Korean Med Sci; 2022 Sep; 37(37):e282. PubMed ID: 36163478
[TBL] [Abstract][Full Text] [Related]
9. Vedolizumab Trough Levels in Children With Anti-Tumor Necrosis Factor Refractory Inflammatory Bowel Disease.
Aardoom MA; Jongsma MME; de Vries A; Wolthoorn J; de Ridder L; Escher JC
J Pediatr Gastroenterol Nutr; 2020 Oct; 71(4):501-507. PubMed ID: 32639455
[TBL] [Abstract][Full Text] [Related]
10. Benefit of measuring vedolizumab concentrations in inflammatory bowel disease patients in a real-world setting.
Kolehmainen S; Ylisaukko-Oja T; Jokelainen J; Koivusalo M; Jokiranta TS; Sipponen T
Scand J Gastroenterol; 2021 Aug; 56(8):906-913. PubMed ID: 34154506
[TBL] [Abstract][Full Text] [Related]
11. Vedolizumab, an option in patients with inflammatory bowel disease intolerant to thiopurines and refractory to biological agents.
Iborra M; Beltrán B; Maroto N; Navarro-Cortés P; Boscá-Watts M; Ferrer-Bradley I; García-Morales N; Sáez-González E; Hinojosa J; Mínguez M; Nos P
Gastroenterol Hepatol; 2018 Nov; 41(9):535-543. PubMed ID: 30031573
[TBL] [Abstract][Full Text] [Related]
12. Fecal calprotectin is a reliable marker of endoscopic response to vedolizumab therapy: A simple algorithm for clinical practice.
Pauwels RWM; de Vries AC; van der Woude CJ
J Gastroenterol Hepatol; 2020 Nov; 35(11):1893-1901. PubMed ID: 32291796
[TBL] [Abstract][Full Text] [Related]
13. Systematic review with meta-analysis: association between vedolizumab trough concentration and clinical outcomes in patients with inflammatory bowel diseases.
Singh S; Dulai PS; Vande Casteele N; Battat R; Fumery M; Boland BS; Sandborn WJ
Aliment Pharmacol Ther; 2019 Oct; 50(8):848-857. PubMed ID: 31483522
[TBL] [Abstract][Full Text] [Related]
14. Soluble Mucosal Addressin Cell Adhesion Molecule 1 and Retinoic Acid are Potential Tools for Therapeutic Drug Monitoring in Patients with Inflammatory Bowel Disease Treated with Vedolizumab: A Proof of Concept Study.
Paul S; Williet N; Di Bernado T; Berger AE; Boschetti G; Filippi J; Del Tedesco E; Nancey S; Flourie B; Roblin X
J Crohns Colitis; 2018 Aug; 12(9):1089-1096. PubMed ID: 29860366
[TBL] [Abstract][Full Text] [Related]
15. Low Rate of Drug Discontinuation, Frequent Need for Dose Adjustment, and No Association with Development of New Arthralgia in Patients Treated with Vedolizumab: Results from a Tertiary Referral IBD Center.
Reinglas J; Gonczi L; Verdon C; Bessissow T; Afif W; Wild G; Seidman E; Bitton A; Lakatos PL
Dig Dis Sci; 2020 Jul; 65(7):2046-2053. PubMed ID: 31813132
[TBL] [Abstract][Full Text] [Related]
16. Switching from intravenous to subcutaneous infliximab and vedolizumab in patients with inflammatory bowel disease: impact on trough levels, day hospital visits, and medical expenses.
Harno-Tasihin J; Siregar L; Paajanen M; Arkkila P; Punkkinen J
Scand J Gastroenterol; 2024 Mar; 59(3):280-287. PubMed ID: 38006219
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Vedolizumab for Induction of Remission in Inflammatory Bowel Disease-the Israeli Real-World Experience.
Kopylov U; Ron Y; Avni-Biron I; Koslowsky B; Waterman M; Daher S; Ungar B; Yanai H; Maharshak N; Ben-Bassat O; Lichtenstein L; Bar-Gil Shitrit A; Israeli E; Schwartz D; Zittan E; Eliakim R; Chowers Y; Ben-Horin S; Dotan I
Inflamm Bowel Dis; 2017 Mar; 23(3):404-408. PubMed ID: 28178003
[TBL] [Abstract][Full Text] [Related]
18. Association of Vedolizumab Level, Anti-Drug Antibodies, and α4β7 Occupancy With Response in Patients With Inflammatory Bowel Diseases.
Ungar B; Kopylov U; Yavzori M; Fudim E; Picard O; Lahat A; Coscas D; Waterman M; Haj-Natour O; Orbach-Zingboim N; Mao R; Chen M; Chowers Y; Eliakim R; Ben-Horin S
Clin Gastroenterol Hepatol; 2018 May; 16(5):697-705.e7. PubMed ID: 29223444
[TBL] [Abstract][Full Text] [Related]
19. Association Between Low Trough Levels of Vedolizumab During Induction Therapy for Inflammatory Bowel Diseases and Need for Additional Doses Within 6 Months.
Williet N; Boschetti G; Fovet M; Di Bernado T; Claudez P; Del Tedesco E; Jarlot C; Rinaldi L; Berger A; Phelip JM; Flourie B; Nancey S; Paul S; Roblin X
Clin Gastroenterol Hepatol; 2017 Nov; 15(11):1750-1757.e3. PubMed ID: 27890854
[TBL] [Abstract][Full Text] [Related]
20. Proactive therapeutic drug monitoring and vedolizumab dose optimization in children with inflammatory bowel disease.
Rowland P; McNicol M; Kiel A; Maltz RM; Donegan A; Dotson JL; Michel HK; Boyle B
J Pediatr Gastroenterol Nutr; 2024 Apr; 78(4):853-861. PubMed ID: 38270212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]